Year-End Report

FOLEY HOAG LLP for AMGEN

Period Year-End 2007 Filed Feb 14, 2008

Official filing
Firm
FOLEY HOAG LLP
Client
AMGEN
Income
$140,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare payment for erythropoiesis stimulating agents

LobbyistCovered position, as disclosed
BRIAN CAREY N/A
PAUL KIM N/A
NICK LITTLEFIELD N/A
DAVID MOHLER N/A
BARRETT THORNHILL N/A

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Follow-on Biologics: S. 623 and H.R. 1038 - Access to Life-Saving Medicines Act, H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007, S. 1695 - Biologics Price Competition and Innovation Act of 2007

LobbyistCovered position, as disclosed
BRIAN CAREY N/A
PAUL KIM N/A
NICK LITTLEFIELD N/A
DAVID MOHLER N/A
BARRETT THORNHILL N/A

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1956 (110th), S. 1695 (110th), H.R. 1038 (110th), S. 623 (110th)

Copyright/Patent/Trademark CPT

Patent Reform Act of 2007--S 1145, HR 1908

LobbyistCovered position, as disclosed
BRIAN CAREY N/A
PAUL KIM N/A
NICK LITTLEFIELD N/A
DAVID MOHLER N/A
BARRETT THORNHILL N/A

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1908 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.